{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:12:59Z","timestamp":1787008379333,"version":"build-2736575974"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistant hypertension (RH) is a multifactorial disease associated with several target organ damage, such as microalbuminuria, left ventricular hypertrophy, and arterial stiffness. These subjects have high cardiovascular complications, especially when associated with diabetes condition. Sodium glucose cotransporter 2 (SGLT-2) inhibitors represent a new class of oral antidiabetic drugs that have shown positive effects in diabetics and even hypertensives subjects. Several studies demonstrated positive outcomes related to blood pressure levels, body weight, and glycemic control. Also found a reduction on microalbuminuria, cardiac and arterial remodeling process, and decrease in hospitalization care due heart failure. Despite these positive effects, the outcomes found for stroke were conflicted and tend neutral effect. Based on this, we sought to assess the pleiotropic effects of SGLT-2 inhibitors and the possible impact in RH subjects. In order to analyze the prospects of SGLT-2 inhibitors as a possible medication to complement the therapy manage of this high-risk class of patients.<\/jats:p>","DOI":"10.1093\/ajh\/hpx204","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T15:12:47Z","timestamp":1511363567000},"page":"274-280","source":"Crossref","is-referenced-by-count":6,"title":["Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects"],"prefix":"10.1093","volume":"31","author":[{"given":"Mariana R","family":"Pioli","sequence":"first","affiliation":[{"name":"Laboratory of Cardiovascular Pharmacology, Department of Pharmacology, School of Medical Sciences, University of Campinas \u2013 UNICAMP, Campinas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra M V","family":"Ritter","sequence":"additional","affiliation":[{"name":"Laboratory of Cardiovascular Pharmacology, Department of Pharmacology, School of Medical Sciences, University of Campinas \u2013 UNICAMP, Campinas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Modolo","sequence":"additional","affiliation":[{"name":"Laboratory of Cardiovascular Pharmacology, Department of Pharmacology, School of Medical Sciences, University of Campinas \u2013 UNICAMP, Campinas, S\u00e3o Paulo, Brazil"},{"name":"Department of Internal Medicine \u2013 Cardiology Division, School of Medical Sciences, University of Campinas \u2013 UNICAMP, Campinas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,23]]},"reference":[{"key":"2022111502391680500_CIT0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/fca.14.27","article-title":"Eighth Joint National Committee guidelines","volume":"10","author":"Aronow","year":"2014","journal-title":"Future Cardiol"},{"key":"2022111502391680500_CIT0002","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"2022111502391680500_CIT0003","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","article-title":"A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension","volume":"388","author":"Olsen","year":"2016","journal-title":"Lancet"},{"key":"2022111502391680500_CIT0004","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.clinthera.2015.03.004","article-title":"The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes","volume":"37","author":"Whalen","year":"2015","journal-title":"Clin Ther"},{"key":"2022111502391680500_CIT0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","article-title":"Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial","volume":"38","author":"Matthaei","year":"2015","journal-title":"Diabetes Care"},{"key":"2022111502391680500_CIT0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022111502391680500_CIT0007","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J"},{"key":"2022111502391680500_CIT0008","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"key":"2022111502391680500_CIT0009","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022111502391680500_CIT0010","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"2022111502391680500_CIT0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/jhh.2015.116","article-title":"Microalbuminuria in subjects with hypertension attending specialist blood pressure clinics","volume":"30","author":"Alharf","year":"2016","journal-title":"J Hum Hypertens"},{"key":"2022111502391680500_CIT0012","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","article-title":"Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study","volume":"139","author":"Wachtell","year":"2003","journal-title":"Ann Intern Med"},{"key":"2022111502391680500_CIT0013","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0272-6386(99)70002-8","article-title":"Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications","volume":"34","author":"Bianchi","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2022111502391680500_CIT0014","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2022111502391680500_CIT0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"2022111502391680500_CIT0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/jhh.2009.35","article-title":"Urinary albumin excretion is associated with true resistant hypertension","volume":"24","author":"Oliveras","year":"2010","journal-title":"J Hum Hypertens"},{"key":"2022111502391680500_CIT0017","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/1479164116657304","article-title":"Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy\/Ta mice, obese and type 2 diabetic animals","volume":"13","author":"Ishibashi","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"2022111502391680500_CIT0018","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jphp.12223","article-title":"Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats","volume":"66","author":"Tahara","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"2022111502391680500_CIT0019","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022111502391680500_CIT0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022111502391680500_CIT0021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/1753-0407.12484","article-title":"Efficacy and safety of dapagliflozin in Asian patients: a pooled analysis","volume":"9","author":"Yang","year":"2017","journal-title":"J Diabetes"},{"key":"2022111502391680500_CIT0022","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022111502391680500_CIT0023","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia"},{"key":"2022111502391680500_CIT0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022111502391680500_CIT0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ejhf.427","article-title":"Incidence of heart failure in 6083 elderly hypertensive patients: the Second Australian National Blood Pressure Study (ANBP2)","volume":"18","author":"Sahle","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2022111502391680500_CIT0026","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ajh\/hpu140","article-title":"Predictors of silent myocardial ischemia in resistant hypertensive patients","volume":"28","author":"Modolo","year":"2015","journal-title":"Am J Hypertens"},{"key":"2022111502391680500_CIT0027","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jch.12773","article-title":"Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension","volume":"18","author":"Egan","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022111502391680500_CIT0028","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","article-title":"Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure","volume":"30","author":"Pellicori","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022111502391680500_CIT0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"2022111502391680500_CIT0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022111502391680500_CIT0031","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022111502391680500_CIT0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","article-title":"Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design","volume":"15","author":"Singh","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0033","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"2022111502391680500_CIT0034","first-page":"150042","article-title":"Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin","volume":"2015","author":"Kaur","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2022111502391680500_CIT0035","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"2022111502391680500_CIT0036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0037","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-016-0381-x","article-title":"Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial","volume":"15","author":"Tanaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0038","doi-asserted-by":"crossref","first-page":"e104362","DOI":"10.1371\/journal.pone.0104362","article-title":"Resistant hypertension, patient characteristics, and risk of stroke","volume":"9","author":"Hung","year":"2014","journal-title":"PLoS One"},{"key":"2022111502391680500_CIT0039","doi-asserted-by":"crossref","first-page":"e5245","DOI":"10.1097\/MD.0000000000005245","article-title":"Short-term hypertension management in community is associated with long-term risk of stroke and total death in China: a community controlled trial","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2022111502391680500_CIT0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1253\/circj.CJ-16-1148","article-title":"Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease- Results from EMPA-REG OUTCOME(\u00ae)","volume":"81","author":"Kaku","year":"2017","journal-title":"Circ J"},{"key":"2022111502391680500_CIT0041","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/dom.12734","article-title":"Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials","volume":"18","author":"Salsali","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022111502391680500_CIT0042","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022111502391680500_CIT0043","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1185\/03007995.2015.1121865","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America","volume":"32","author":"Lavalle-Gonz\u00e1lez","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2022111502391680500_CIT0044","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"2022111502391680500_CIT0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/2047487316672004","article-title":"Plasma and blood viscosity in the prediction of cardiovascular disease and mortality in the Scottish Heart Health Extended Cohort Study","volume":"24","author":"Peters","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2022111502391680500_CIT0046","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/heart.89.9.1104","article-title":"Cardiac and vascular pathophysiology in hypertension","volume":"89","author":"Mayet","year":"2003","journal-title":"Heart"},{"key":"2022111502391680500_CIT0047","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10641963.2011.618205","article-title":"Echocardiographic abnormalities in the assessment of cardiac organ damage in never-treated hypertensive patients","volume":"34","author":"Milan","year":"2012","journal-title":"Clin Exp Hypertens"},{"key":"2022111502391680500_CIT0048","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/HJH.0000000000000280","article-title":"Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension","volume":"32","author":"Azizi","year":"2014","journal-title":"J Hypertens"},{"key":"2022111502391680500_CIT0049","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/01.HYP.0000156878.17006.02","article-title":"Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system","volume":"45","author":"Booz","year":"2005","journal-title":"Hypertension"},{"key":"2022111502391680500_CIT0050","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"2022111502391680500_CIT0051","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0052","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0053","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/hrt.2009.177238","article-title":"Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass","volume":"96","author":"Simpson","year":"2010","journal-title":"Heart"},{"key":"2022111502391680500_CIT0054","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cjca.2016.02.070","article-title":"Vascular fibrosis in aging and hypertension: Molecular mechanisms and clinical implications","volume":"32","author":"Harvey","year":"2016","journal-title":"Can J Cardiol"},{"key":"2022111502391680500_CIT0055","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s40265-016-0642-8","article-title":"Drug treatment of hypertension: focus on vascular health","volume":"76","author":"Cameron","year":"2016","journal-title":"Drugs"},{"key":"2022111502391680500_CIT0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10741-015-9471-1","article-title":"The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis","volume":"20","author":"Chow","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2022111502391680500_CIT0057","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"key":"2022111502391680500_CIT0058","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/08037051.2011.617045","article-title":"Vascular stiffness and endothelial dysfunction: correlations at different levels of blood pressure","volume":"21","author":"Figueiredo","year":"2012","journal-title":"Blood Press"},{"key":"2022111502391680500_CIT0059","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/01.HYP.0000239206.64270.5f","article-title":"Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans","volume":"48","author":"McEniery","year":"2006","journal-title":"Hypertension"},{"key":"2022111502391680500_CIT0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11906-017-0704-7","article-title":"Arterial (aortic) stiffness in patients with resistant hypertension: from assessment to treatment","volume":"19","author":"Sharman","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"2022111502391680500_CIT0061","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","article-title":"Expert consensus document on arterial stiffness: methodological issues and clinical applications","volume":"27","author":"Laurent","year":"2006","journal-title":"Eur Heart J"},{"key":"2022111502391680500_CIT0062","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022111502391680500_CIT0063","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0064","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.atherosclerosis.2012.05.022","article-title":"Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms","volume":"223","author":"Cooper","year":"2012","journal-title":"Atherosclerosis"},{"key":"2022111502391680500_CIT0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1475-2840-11-114","article-title":"Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial","volume":"11","author":"Hughes","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"2022111502391680500_CIT0066","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/HYPERTENSIONAHA.109.133801","article-title":"Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension","volume":"54","author":"Mackenzie","year":"2009","journal-title":"Hypertension"},{"key":"2022111502391680500_CIT0067","doi-asserted-by":"crossref","first-page":"542042","DOI":"10.1155\/2012\/542042","article-title":"Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats","volume":"2012","author":"Osorio","year":"2012","journal-title":"Oxid Med Cell Longev"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/3\/274\/47041869\/ajh_31_3_274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/3\/274\/47041869\/ajh_31_3_274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T21:40:08Z","timestamp":1668462008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/31\/3\/274\/4653681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,11,23]]},"published-print":{"date-parts":[[2018,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpx204","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2017,11,23]]}}}